Gefitinib

證據等級: L5

預測適應症: 10 個

Gefitinib: From EGFR-Mutant Non-Small Cell Lung Cancer to Fibromatosis, Gingival

One-Sentence Summary

Gefitinib is an EGFR (HER1) tyrosine kinase inhibitor known for treating EGFR-mutation-positive non-small cell lung cancer (NSCLC). The TxGNN model’s top-ranked prediction for this drug is Fibromatosis, Gingival, with a prediction score of 99.89%, but this candidate currently has 0 clinical trials and 0 publications supporting it — the evidence pack itself flags no known mechanistic connection between EGFR inhibition and this condition.

Quick Overview

Item	Content
Original Indication	EGFR-mutant Non-Small Cell Lung Cancer (NSCLC) — inferred from mechanistic rationale text embedded in the evidence pack; formal Taiwan license record unavailable (data gap)
Predicted New Indication	Fibromatosis, Gingival
TxGNN Prediction Score	99.89%
Evidence Level	L5 (model prediction only, no supporting studies)
Market Status (Taiwan)	Not Marketed
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data for gefitinib is flagged as a data gap in this evidence pack (DG002). However, other candidate entries in the same pack consistently describe gefitinib as an EGFR (HER1) tyrosine kinase inhibitor, approved for EGFR-mutation-positive NSCLC — this is well-established background knowledge for this drug and is corroborated repeatedly across the pack’s own rationale text.

For the top-ranked candidate, Fibromatosis, Gingival, the evidence pack’s own repurposing rationale states this condition is primarily associated with connective-tissue overgrowth and hereditary fibrotic mechanisms, with no known connection to EGFR inhibition. No clinical trials, ICTRP trials, or PubMed literature were found linking gefitinib to this disease. This candidate appears to reflect the TxGNN model’s raw prediction score rather than any mechanistic or clinical signal — consistent with its assigned Evidence Level L5 and Hold recommendation.

By contrast, two lower-ranked candidates in this same pack — lung hilum carcinoma (rank 5) and pulmonary sulcus neoplasm (rank 8) — are anatomical subtypes of NSCLC and align directly with gefitinib’s already-approved mechanism; both reached decision stage S1 (“Research Question”). These may warrant separate evaluation (see Conclusion).

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

Currently no related literature available

Cytotoxicity

Gefitinib is an EGFR-targeted small-molecule tyrosine kinase inhibitor used in non-small cell lung cancer, meeting the antineoplastic classification criteria.

Item	Content
Cytotoxicity Classification	Targeted therapy (EGFR/HER1 tyrosine kinase inhibitor) — not a conventional cytotoxic agent
Myelosuppression Risk	Low — TKIs of this class are not classically myelosuppressive; formal hematologic toxicity data is a data gap (DrugBank query returned no MOA/toxicity detail)
Emetogenicity Classification	Low
Monitoring Items	Liver function tests (hepatotoxicity); chest imaging/pulmonary function for interstitial lung disease (per literature PMID 22076388); ECG/QTc (per PMID 34474028 and PMID 37258113); skin examination for acneiform eruption (per PMID 18931563); CBC
Handling Protection	Oral formulation, targeted small molecule — does not require IV cytotoxic handling precautions, but institutional oncology-drug handling policy should still be followed; please refer to the package insert for confirmation

Safety Considerations

Please refer to the package insert for safety information. (TFDA label warnings, contraindications, and DDI data are currently unavailable — flagged as a Blocking data gap, DG001.)

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked prediction (Fibromatosis, Gingival) has a high TxGNN score but no clinical trials, no literature, and no plausible mechanistic link per the evidence pack itself — this is a model-score-only signal (L5) with no basis for further action.

To proceed, the following is needed:

TFDA label (warnings/contraindications) — currently a Blocking data gap (DG001)
Confirmed mechanism-of-action record from DrugBank (DG002)
Consider separately evaluating lung hilum carcinoma and pulmonary sulcus neoplasm from this same evidence pack — both are NSCLC anatomical subtypes with mechanistic continuity to gefitinib’s approved use and reached decision stage S1 (“Research Question”), unlike the Fibromatosis, Gingival candidate reported here
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.